SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 81 filers reported holding SPERO THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,744 | -16.6% | 6,400 | 0.0% | 0.00% | – |
| Q2 2023 | $9,280 | 0.0% | 6,400 | 0.0% | 0.00% | – |
| Q1 2023 | $9,280 | -16.2% | 6,400 | 0.0% | 0.00% | – |
| Q4 2022 | $11,072 | -7.7% | 6,400 | 0.0% | 0.00% | – |
| Q3 2022 | $12,000 | +200.0% | 6,400 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -93.7% | 6,400 | -11.7% | 0.00% | – |
| Q1 2022 | $63,000 | -45.7% | 7,250 | 0.0% | 0.00% | – |
| Q4 2021 | $116,000 | -22.1% | 7,250 | -11.0% | 0.00% | – |
| Q3 2021 | $149,000 | -38.2% | 8,147 | -53.1% | 0.00% | – |
| Q2 2021 | $241,000 | -66.7% | 17,369 | -64.7% | 0.00% | -100.0% |
| Q1 2021 | $723,000 | -28.1% | 49,167 | -5.0% | 0.00% | -50.0% |
| Q4 2020 | $1,005,000 | -22.3% | 51,767 | -55.6% | 0.00% | -33.3% |
| Q3 2020 | $1,293,000 | +2.6% | 116,528 | +24.9% | 0.00% | 0.0% |
| Q2 2020 | $1,260,000 | +1365.1% | 93,328 | +768.9% | 0.00% | – |
| Q1 2020 | $86,000 | +56.4% | 10,741 | +83.0% | 0.00% | – |
| Q4 2019 | $55,000 | +292.9% | 5,868 | +351.4% | 0.00% | – |
| Q3 2018 | $14,000 | -51.7% | 1,300 | -35.0% | 0.00% | – |
| Q2 2018 | $29,000 | – | 2,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |